Neurology

MemorialCare Long Beach Medical Center Becomes First in California to Adopt Stryker’s New Q Guidance System with Spine Guidance SoftwareMemorialCare Long Beach Medical Center Becomes First in California to Adopt Stryker’s New Q Guidance System with Spine Guidance Software

MemorialCare Long Beach Medical Center Becomes First in California to Adopt Stryker’s New Q Guidance System with Spine Guidance Software

Advanced surgical planning and navigation technology enhances precision and expands options for spine surgery, cutting down the length of surgery,…

2 months ago
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech ConferenceCabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and…

2 months ago
ANI Pharmaceuticals to Present at the Guggenheim Biotech ConferenceANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that…

2 months ago
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet NeurologyFindings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet Neurology

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet Neurology

The first investigational FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+,…

2 months ago
Nxera Pharma Webinar Presentation for FY2024 Financial ResultsNxera Pharma Webinar Presentation for FY2024 Financial Results

Nxera Pharma Webinar Presentation for FY2024 Financial Results

Tokyo, Japan and Cambridge, UK, 23 January 2025 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings…

2 months ago
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal ForalumabTiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

2 months ago
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical OperationsTenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a…

2 months ago
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung DiseasesEvotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry…

2 months ago
Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEOOragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for…

2 months ago